Register for ERT Does Not Appear To Increase Recurrence Risk
Endometrial CancerApril 12, 2001
2001 APR 12 - (NewsRx.com & NewsRx.net) -- Use of estrogen replacement therapy (ERT), with or without progestins, among women diagnosed with endometrial cancer does not appear to increase their risk of recurring cancer or death, says new research from the University of California-Irvine.
ERT for women with a history of endometrial cancer remains controversial. Physicians have historically withheld ERT from these patients based on the theoretical risk that estrogen may stimulate a recurrence of cancer.
But, according to research in the April 2001 issue of Obstetrics & Gynecology, women who received ERT after their cancer treatments remained disease-free significantly longer than a group of similar women who did not receive ERT.
Endometrial cancer, the fourth most common cancer in American women, has an overall cure rate of over 70%.
For additional information, contact Philip J. DiSaia, MD, University of California, Irvine Medical Center, Orange, CA, USA. E-mail: pjdisaia@uci.edu. This article was prepared by Women's Health Weekly editors from staff and other reports.
©Copyright 2000, Women's Health Weekly via NewsRx.com & NewsRx.net
